Daclizumab induction therapy in combination with tacrolimus

Markus, B. H.; Weber, Sabine; Allers, C.; Hauser, Ingeborg A.; Encke, A.

doi:10.1016/s0041-1345(00)02535-5

Cited by 4 publications

(1 citation statement)

References 7 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Daclizumab, a humanized monoclonal antibody that targets the 55‐kDa alpha chain of the interleukin‐2 receptor, suppresses clonal expansion of antigen‐activated T cells critical for causing acute allograft rejection [21,22]. Daclizumab has been widely evaluated in renal transplantation but has only recently been studied in liver transplant recipients, mainly as a calcineurin inhibitor‐sparing agent in the setting of perioperative renal impairment [23–31]. In the vast majority of the studies, the efficacy and tolerability of regimens including daclizumab and reduced doses of calcineurin inhibitors were similar to those achieved with standard immunosuppressive regimens not including daclizumab.…”

Section: Introductionmentioning

confidence: 99%

Daclizumab induction and maintenance steroid-free immunosuppression with mycophenolate mofetil and tacrolimus to prevent acute rejection of hepatic allografts

Figueras¹,

Prieto²,

Bernardos³

et al. 2006

Transplant Int

View full text Add to dashboard Cite

Summary Steroid‐free immunosuppressive regimens reduce corticosteroid‐related side effects in liver transplant recipients although their efficacy is very variable. We evaluated the efficacy and safety of a steroid‐free regimen in a 6‐month, open‐label, multicenter, pilot study, which involved 102 liver transplant patients treated with daclizumab (2 mg/kg within 6 h following transplant and 1 mg/kg on day 7), mycophenolate mofetil (MMF, 1 g b.i.d) and tacrolimus (trough levels of 5–15 ng/ml in the first month and 5–10 ng/ml thereafter). One intra‐operative dose of methylprednisolone was administered. At 6 months, the acute rejection rate was 9.8%, and patient and graft survival rates were 96% and 95%, respectively. Acute rejection rates were similar for hepatitis C‐positive patients (8.6%) and hepatitis C‐negative patients (10.4%). Infections occurred in 22% of patients; most cases were considered mild or moderate. Post‐transplantation hypertension and diabetes mellitus developed in 37% and 14% of patients, respectively, during the study period, but were markedly less frequent (8% and 6%, respectively) at 6 months. Hypercholesterolemia was observed in only 2% of patients. In conclusion, the steroid‐free immunosuppressive regimen of daclizumab, MMF, and tacrolimus effectively prevents acute rejection after liver transplantation without decreasing safety.

show abstract

Section: Introductionmentioning

confidence: 99%